Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Cameron Health's subcutaneous ICD for sudden cardiac arrest receives FDA advisory panel approval

Cameron Health, Inc., a pioneer in the development, manufacture and distribution of next generation implantable cardioverter defibrillators (ICDs), announced today that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel voted 7-1 that sufficient data exists demonstrating the efficacy and safety of the S-ICD System for the treatment of sudden cardiac arrest (SCA).

27 Apr 2012

Cardiovascular emergencies may benefit from regionalized systems of care

Experts are proposing a new model of care collaboration to diagnosis, treat and follow patients who present with various emergent cardiovascular conditions which require rapid, resource-intensive care and confer a high risk of mortality, in an article published April 24 in Circulation.

26 Apr 2012

Therapeutic hypothermia reduces in-hospital deaths among sudden cardiac arrest patients

Forced body cooling known as therapeutic hypothermia has reduced in-hospital deaths among sudden cardiac arrest patients nearly 12 percent between 2001 and 2009, according to a Mayo Clinic study being presented at the upcoming American Academy of Neurology 2012 Annual Meeting in New Orleans.

20 Apr 2012

FDA approves Medtronic’s expanded indication for implantable CRT-D devices

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices.

From Medtronic 11 Apr 2012

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

In collaboration with a Brussels University team under the leadership of Nick Devoogdt and a French team from INSERM, Serge Muyldermans and his team, associated with VIB and Vrije Universiteit Brussel, have succeeded in developing the first patient-friendly, non-invasive method for differentiating dangerous strictures in blood vessels, so-called vulnerable atherosclerotic plaques, from less dangerous ones.

5 Apr 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Heart attack could be treated best with cheap mix of three injections: Study

When the shot was given early to patients with signs of a heart attack, the mixture of glucose, insulin and potassium (GIK), showed remarkable success in preventing full cardiac arrest - when the heart stops beating - and even death. And each shot cocktail costs only about $US50, according to the research presented at the American College of Cardiology's 61st annual scientific meeting in Chicago. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.

28 Mar 2012

Out-of-hospital use of GIK as therapy for ACS patients needs to be assessed

Patients experiencing symptoms such as chest pain who received from paramedics an intravenous solution consisting of glucose-insulin-potassium (GIK) had no reduction in the rate of progression to heart attack and no improvement in 30-day survival, although GIK was associated with a lower rate of the composite outcome of cardiac arrest or in-hospital death, according to a study appearing in JAMA.

28 Mar 2012

GIK can reduce cardiac arrest or death in patients with acute coronary syndrome

Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

28 Mar 2012

New CMS requirement increases ICD placement costs

The cost to place an implantable cardioverter-defibrillator (ICD) increased by $844 per case after a new requirement from the Centers for Medicare and Medicaid Services (CMS) went into effect in February 2010, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Lower BMI increases risk during insertion of ICDs

Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

Diabetics less likely to survive in-hospital cardiac arrest

Patients with high blood sugar run an increased risk of dying if they have a heart attack, and diabetics are less likely to survive in-hospital cardiac arrest than non-diabetics, reveals research at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

26 Mar 2012

EACP recommends minimum standards for emergency cardiovascular care at stadiums

Cardiac arrest during professional sports activities has occurred in the past. Unfortunately, this has not led to a general improvement of the situation in Europe. The recent case of British football player Fabrice Muamba is, regretfully, a sad reminder of the need to adhere to existing guidelines for the screening of athletes and for the safety in big gatherings, especially (but not only) in professional sports events.

22 Mar 2012

FDA panel to review Cameron Health S-ICD System PMA application

Cameron Health, Inc. announced today that the U.S. Food and Drug Administration Circulatory System Devices Panel will review the Premarket Approval (PMA) application of the S-ICD System on April 26, 2012.

19 Mar 2012

Study confirms value of Cambridge Heart's MTWA test for SCA

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that a new study published on-line in the Heart Rhythm Journal confirms the value of Microvolt T-Wave Alternans (MTWA) testing for identifying patients at risk of sudden cardiac arrest.

19 Mar 2012

Japan's MHLW provides reimbursement coverage for MTWA test

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that its Microvolt T-Wave Alternans (MTWA) test received reimbursement coverage from Japan's Ministry of Health, Labor and Welfare (MHLW).

17 Mar 2012

UM, Shock Trauma partner to train dental students, residents

The University of Maryland's (UM) School of Dentistry has teamed up with the UM School of Medicine's R Adams Cowley Shock Trauma Center for training future dentists to respond efficiently and effectively to life threatening medical emergencies in a dental setting.

16 Mar 2012

Boston Scientific in bid to take over Cameron Health

Boston Scientific, the second-biggest cardiac-device maker, will pay $150 million when the deal closes and another $150 million if Cameron’s technology called the S-ICD System wins U.S. Food and Drug Administration approval, the Natick, Massachusetts-based company said in a statement yesterday.

12 Mar 2012

Boston Scientific exercises option to acquire Cameron Health

Boston Scientific Corporation announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California.

9 Mar 2012

Pharmacological antagonist can inhibit body's response to cold

Researchers at St. Joseph's Hospital and Medical Center in Phoenix, Arizona, in collaboration with Amgen Inc. and several academic institutions, have discovered a way to block the body's response to cold using a drug. This finding could have significant implications in treating conditions such as stroke and cardiac arrest.

2 Mar 2012